Literature DB >> 6461669

In vitro responses to a B-lymphoblastoid cell line in immunodeficiency diseases.

J L Sullivan, H D Ochs, R J Wedgwood.   

Abstract

The use of a B-lymphoblastoid cell line (B-L-CL) as a stimulator cell in the mixed leukocyte reaction (MLR) was investigated in patients with immunodeficiency disorders. The kinetics of the MLR stimulated by B-L-CL are similar to those stimulated by normal allogeneic leukocytes, however, B-L-CL stimulate a greater quantitative response. Comparison of a LCL-stimulated and normal allogeneic lymphocyte-stimulated MLR in 32 patients and normal controls demonstrated that variation in the MLR was reduced when B-LCL were used as stimulator cells. The decrease in variability allowed for more sensitivity in the determination of abnormal responses; 9 of 32 patients had abnormal B-LCL-stimulated MLC responses, compared with 5 of 32 patients with abnormal responses to normal allogeneic leukocytes. Dose-response studies showed that vigorous responses could be obtained with low doses of B-LCL stimulator cells which served to better define deficient patient responses. Several patients demonstrated dissociation between the B-LCL-stimulated MLR and mitogen responses. The use of a B-LCL as a stimulator in the MLR is a valuable tool for the assessment of the immune status of patients with a variety of immunodeficiency disorders.

Entities:  

Mesh:

Year:  1982        PMID: 6461669     DOI: 10.1007/bf00916899

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  12 in total

1.  Lymphoblastoid cells as stimulators in mixed lymphocyte reactions in medium with bovine serum albumin.

Authors:  S Hsia; D B Amos
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

2.  Long term effects of radiation of T and B lymphocytes in peripheral blood of patients with Hodgkin's disease.

Authors:  Z Fuks; S Strober; A M Bobrove; T Sasazuki; A McMichael; H S Kaplan
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

3.  Cytogenetic study of human lymphoid T-cell lines derived from lymphocytic leukemia.

Authors:  C C Huang; Y Hou; L K Woods; G E Moore; J Minowada
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

4.  DiGeorge syndrome associated with combined immunodeficiency. Dissociation of phytohemagglutinin and mixed leukocyte culture responses.

Authors:  R A Gatti; J J Gershanik; A H Levkoff; W Wertelecki; R A Good
Journal:  J Pediatr       Date:  1972-11       Impact factor: 4.406

5.  Lymphocyte studies in congenital thymic dysplasia: The one-way stimulation test.

Authors:  H J Meuwissen; F H Bach; R Hong; R A Good
Journal:  J Pediatr       Date:  1968-02       Impact factor: 4.406

6.  Lymphoblastoid cell lines of homozygous typing cells used for sensitization in PLT.

Authors:  N Reinsmoen; E J Yunis; F H Bach; M L Bach
Journal:  Tissue Antigens       Date:  1977-01

7.  Lymphoblastoid cell lines are polyclonal activators of human T lymphocytes.

Authors:  A W Boylston; R L Anderson
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

8.  Defective lymphocyte transformation and delayed hypersensitivity in Wiskott-Aldrich syndrome.

Authors:  J J Oppenheim; R M Blaese; T A Waldmann
Journal:  J Immunol       Date:  1970-04       Impact factor: 5.422

9.  Lymphocyte transformation induced by autologous cells. III. Lymphoblast-induced lymphocyte to stimulation does not correlate with EB viral antigen expression or immunity.

Authors:  M E Weksler
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

10.  Abnormalities of immunoregulatory T cells in disorders of immune function.

Authors:  E L Reinherz; A Rubinstein; R S Geha; A J Strelkauskas; F S Rosen; S F Schlossman
Journal:  N Engl J Med       Date:  1979-11-08       Impact factor: 91.245

View more
  1 in total

1.  X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency.

Authors:  J L Sullivan; K S Byron; F E Brewster; S M Baker; H D Ochs
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.